ACTB

 The PPI analysis identified several biological process GO terms such as "Actin cytoskeleton organization," "Box C/D snoRNP assembly," "Actin filament depolymerization," "Cell junction assembly," and "DNA repair."

The current study aimed to analyze the diagnostic value of ACTB and predict its independent prognostic factor in distinct cancer subtypes using detailed in silico analysis.

The findings suggest that due to its elevated expression, association with poorer survival and metastasis, and correlation with important parameters such as immune infiltration and tumor purity, ACTB has the potential to be a candidate biomarker for LIHC, HNSC, and LUAD.

The dysregulation and polymerization of ACTB have been revealed to be associated with the metastasis of different cancer types.

Warfarin and aflatoxin B1 were found to potentially reduce the expression level of ACTB.

Ten highly significant TFs were identified as potential regulators of ACTB expression. They are AATF, WWTR1, GFI1, NR3C1, MYC, GFI1, STAT3, ING1, MAX, and POU4F1.

The results indicate that a variety of different regulators, including miRNAs and TFs, are involved in the regulation of ACTB expression.

Enrichr analysis was used to identify potential regulators of ACTB expression.

The molecular functions associated with the ACTB-associated genes included "Actin monomer binding," "ATPase activity," "Leucine zipper domain binding," and "DNA helicase activity."

Valporic acid and metribolone were found to potentially elevate the expression level of ACTB.

ACTB serves as a housekeeping gene commonly used as a control in measuring gene expression in various diseases.

Ten miRNAs were identified as potential regulators of ACTB expression. They are hsa-miR-1908, hsa-miR-663, hsa-miR-744, hsa-miR-4745-3p, hsa-miR-1538, hsa-miR-3960, hsa-miR-4749-5p, hsa-miR-4706, hsa-miR-4743, and hsa-miR-3180-3p.

Elevated ACTB expression was associated with poorer survival and metastasis specifically in liver hepatocellular carcinoma (LIHC), head and neck squamous cancer (HNSC), and lung adenocarcinoma (LUAD).

The PPI analysis revealed a set of ten ACTB-associated genes that are involved in various biological processes, including "Actin cytoskeleton organization," "Box C/D snoRNP assembly," "Actin filament depolymerization," "Cell junction assembly," and "DNA repair."

The study utilized in silico analysis to assess the diagnostic value and independent prognostic factor of ACTB in different cancer subtypes.

Through CTD analysis, it was observed that ACTB expression can potentially be influenced by a number of drugs.

 ACTB expression has been found to be closely related to various cancers, including liver, pancreatic, renal, colorectal, melanoma, prostate, esophageal, lung, gastric, breast, and ovarian cancers.

The study explored ACTB-associated clinically important expression regulators, including TFs (transcription factors), miRNAs, and different chemotherapeutic drugs.

ACTB expression was found to be remarkably higher in 24 major human cancer tissues compared to normal samples.

ACTB up-regulation showed interesting correlations with immune infiltration of CD4+ T and CD8+ T cells, tumor purity, mutant genes, and other important parameters.